Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 15,608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Completed Phase 1 Interventional Results available

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions
MDX-1106
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

NCT00878072
View directory record Official record
Conditions
Herpes Labialis
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
San Diego, California • Chicago, Illinois • Evansville, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 31, 2026, 5:41 AM EDT
Terminated Not applicable Interventional Results available

The GORE Viabahn Endoprosthesis for the Treatment of Venous Occlusions and Stenoses

NCT01406795
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Gore Viabahn Heparin Coated Stent
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

NCT01598077
View directory record Official record
Conditions
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
Interventions
LJM716
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 31, 2026, 5:41 AM EDT
Not listed Not applicable Interventional

Testing Pediatric Rheumatology Diagnostic Decision Support in Clinical Use

NCT03501667
View directory record Official record
Conditions
Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)
Interventions
Use of decision support tool, Use of UpToDate
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
25 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Results available

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

NCT02120469
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative, Stage IV Breast Cancer, Triple-negative Breast Carcinoma
Interventions
everolimus, eribulin mesylate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Duarte, California • Rancho Cucamonga, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Early Phase 1 Interventional

Curcumin in Rheumatoid Arthritis

NCT00752154
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Curcumin (Longvida™)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Beverly Hills, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 31, 2026, 5:41 AM EDT
Withdrawn Phase 2 Interventional

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

NCT03872505
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Durvalumab, Radiation Therapy, Carboplatin, Paclitaxel
Drug · Radiation
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

NCT07661966
View directory record Official record
Conditions
Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
Interventions
Bright Light Therapy
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 4 Interventional

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

NCT00437151
View directory record Official record
Conditions
Acne
Interventions
More frequent than normal office visits, Electronic reminders (voice, e-mail, text messages), Parenteral involvement / intervention reminders, No intervention or reminders
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

NCT01575522
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT03050151
View directory record Official record
Conditions
Atopic Disorders, Eczema, Atopic
Interventions
Dupilumab, Auto-injector Device, Prefilled syringe
Drug · Device
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus

NCT00730002
View directory record Official record
Conditions
Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Magnetic Resonance Angiography (MRA), Magnetic resonance imaging, MRA, diffusion Imaging, perfusion imaging.
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 31, 2026, 5:41 AM EDT
Not listed No phase listed Observational

A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients

NCT04699695
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Biologic therapy versus no biologic therapy
Other
Lead sponsor
DermTech
Other
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

A Study of Different Use Regimens Using Two Acne Treatments

NCT00907257
View directory record Official record
Conditions
Acne Vulgaris
Interventions
benzoyl peroxide wash, Tretinoin gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boca Raton, Florida • Miami, Florida • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 31, 2026, 5:41 AM EDT
Terminated Phase 1 Interventional

Safety Study of Multikine in the Treatment of Perianal Warts

NCT02115919
View directory record Official record
Conditions
Condyloma
Interventions
Leukocyte Interleukin, Injection 200IU, Leukocyte Interleukin, injection 400IU
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 31, 2026, 5:41 AM EDT
Terminated No phase listed Observational

Measuring the Effect of Radiation Therapy on Patient Activity Levels

NCT02694380
View directory record Official record
Conditions
Head and Neck Cancer, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection and Distribution of Biospecimens for Novel Research Uses

NCT03848962
View directory record Official record
Conditions
Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases, Infectious Disease, Women's Health: High-Risk Pregnancy, Dermatologic Disease, Blood Disease
Interventions
Not listed
Lead sponsor
iSpecimen Inc
Industry
Eligibility
1 Month to 89 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Huntsville, Alabama • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 31, 2026, 5:41 AM EDT
Withdrawn Phase 2 Interventional

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

NCT01355562
View directory record Official record
Conditions
Melanoma, Metastatic Kidney Cancer
Interventions
Interleukin-2 (IL-2)
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Beaumont, California • Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

NCT00669942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

NCT06939686
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Interventions
Miro3D Wound Matrix, Standard of Care (SOC)
Device · Other
Lead sponsor
Reprise Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Coconut Creek, Florida • Tamarac, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 31, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

NCT01547741
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
914
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Two Heel Protection Devices to Assess Off-loading Via Pressure Mapping.

NCT07734220
View directory record Official record
Conditions
Pressure Injuries
Interventions
HeelMedix Basic & EHOB Waffle
Device
Lead sponsor
Medline Industries
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Northfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

NCT05496296
View directory record Official record
Conditions
Pressure Ulcers Stage II, Pressure Ulcers Stage III, Pressure Ulcer, Stage IV
Interventions
Altrazeal® Transforming Powder Dressing
Device
Lead sponsor
ULURU Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 31, 2026, 5:41 AM EDT